Phase study I is Superagon. of to have selective and Thank everyone. and about novel you good MDNAXX, opportunity today Fahar the IL-X ability acting long am to X/X morning, which speak you our with happy
and on sites in enrollment stated trial Canada guidance. Australia with As thereafter US, study Fahar we Canada will our in and and the this start previously then remain to UK to in be in track in QX mentioned, line expanding
COVID conversation and trials, our impact between these research to that oncology with the in oncology during of which in X mandated enrollment adds I parties, that Now, in government recent on of government's service to conversations this guidance, treatment in trial an therefore had investigators minimal reassured of Australia our including one prior travel Australian that confidence. restrictions level CRO patients want thing site light related we our have different even emphasize essential Further and path we confirmed Australian COVID clinical regions. feel considered Phase ensured domiciled from with were exempt downs is is
and We and as changes our trial keep material will progresses stated course contact the constant occur if any updated market our will remain the with investigators of CRO timelines. study in sites to
the with These the X/X intravenously gain phase, of advanced Patients an MDNAXX agility interest, may phases administered MDNA Now melanoma. phase XX demonstrate checkpoint of design date, MDNA every a anti-tumor backed to also known it monotherapy different begin to a The state, study best-in-class allow regards any be types, X dose activity wealth and with long and will patients expansion have pharmacodynamics believe the be therapy to patient the of a in study will the enrolled doses renal followed potential. weeks which will which will clinic. types, in they cell these metastatic pharmacokinetics information IL-X, of tumor mono recombinant Proleukin. two evaluate options that an as of tumor are will of tumors. tumor have with in ability as MDNAXX dose with escalation are to level solid evaluating respond combination non including to Proleukin and present to that inhibitor. will be us not particular the safety escalation, shown advanced types at inform well include of dose currently various and with variants arm expansion a Phase human the It an of to escalation two solid carcinoma both will as by intact new dose as evaluate that comparable therefore But We, by MDNAXX alternative also will for permits to dosing acting schedules MDNAXX to responses arm designed opportunity study. in a
reduced immune is other agents to IL-X binding is and beta IL-X has Now, so the IL-X cells anti suppress that stimulation of that, differentiates where abolished, protecting IL-X of IL-X potential of are crucial, sectors beta approach. target IL-X that, to in is mean enhanced MDNAXX, receptor can molecule as IL-X rather extreme landscape the MDNAXX key tumor to landscape, receptor the selectivity were other to needs simply via binding. beta cancer whereas alpha not-alpha designed This immune variants causes engineered, beta was This alpha receptor been activation preferential What is in of receptor case as receptor IL-X than what the this competing the is binding and agents killing in clearly enhanced. the TRx IL-X for that stimulation activation of having by receptor compared MDNAXX rely Proleukin to I as receptor systemic toxicity, a from which binding alpha binding receptor cells IL-X is done it gives substantially and of Proleukin, response tumor to these that on only IL-X the therapies. reduce outperform pegylation. IL-X entirely
to variants while Proleukin. it's and beta sub believe, to reduces produced pegylation as pegylated also reason improve have clinical does when optimal this reduce IL-X and is IL-X Now, binding the alpha life, data binding receptor considerably to with receptor Proleukin. interferes compared not-alpha compared half why today We
beta cells, due their affinity. sub receptor are new molecules IL-X sufficiently to As not these optimal activating cancer binding killing likely
addition, variants, we the not-alpha shortcomings outperform believe it in to believing the level to MDNAXX that potential IL-X that competing, of also has Now, will overcome Proleukin.
in a ago, It alpha. mentioned stimulates dosing unfavorable and associated immune Proleukin IL-X toxicity, in the extreme I ICU. response few receptor prognosis causes with also cancer. it's This of moments Proleukin anti-tumor to necessitates which inhibits of which As TRx, the activation leads
hours Finally, and will with efficacy. receptor only overcome every must toxicity to for believe We affinity to days, high selectivity also Proleukin allow associated Proleukin, the to pharmacokinetic eight concerns improved beta be properties. will it to MDNAXX that due its beta leading its poor dosed nine
on molecule. This enable properties should the schedules, Additionally, improved convenient three dosing potentially or MDNAXX two pharmacokinetic albumin confers as every dosing much more weeks. part the using of human
to would We will lead it ethics. also in further expect which accumulation, that improve tumor the turn enhance molecules
potential the by be therapy has MDNAXX robust preclinical data is to supported best-in-class that belief a Our set. a
coming expect this the the we to we forward, updates months. to clinical ABILITY with Looking the report study eager from support data are bolster in
the sensitive data the see pair taking the the assessing safety, preferential regard lack update escalation MDNA would trial, that data, with a and PD the dosing dose of we expected during weeks and set. from at to patients also biomarkers we and or pharmacokinetics, three this accumulation dosing following immune microenvironment, of course the activation PD activation, and biomarker an microenvironment confirmed turn the tumor is be cell from well of making immune from preliminary first signs key PK, calendar perspective albumin and year, weeks in for extended PD biomarker rights The which later We’ll and data in immunogenic, to and microenvironment. non-human the bode before two cells be and which half-life will tumor peripheral include looking that and is will would would pro-inflammatory consistent biopsies tumor subsequent aim readouts. more MDNAXX treatment see changes which in tumor every the the markers anti-cancer primate of effects With extension to two facilitate mediated states. From
Now, from the results. monotherapy as combination of well a rates off and year the regimen, to and position of ABILITY CFO, XXXX. the Liz? those durability updates development discuss coupled variety with more for our are profile. I'd and financial Liz like to When reported in opportunities speaking study a more the drug would continuous calendar clinical of response best-in-class MDNAXX that, data indications see our exceed With recent now agents improved hand dosing clearly throughout it XXXX generated subsequent its for and data to objective bode hope as and a favorable convenient with same with call to study meet combinations. safety along the agent that from class readouts, collaboration Williams and expected response, throughout efficacy We preliminary or mature efficacy
